Alacris Theranostics GmbH

General information
Alacris Theranostics GmbH
Max-Planck-Straße 3
12489 Berlin, Berlin
Germany

Contact person: Bodo Lange, Chief Executive Officer
Company main phone: +49 (30) 84312250
Website:  https://www.alacris.de
Year founded:2008
Source of foundation:Spin-off from public institution / NPO
Name of foundation source:Max Planck Institute for Molecular Genetics
Corporate description / mission:
Alacris Theranostics GmbH's mission is to empower every cancer patient with the benefits of precision medicine. With a passionate team translating research into patient-centered diagnostic solutions, Alacris offer accredited Dx services that combine state-of-the-art Next Generation Sequencing (NGS) with a proprietary bioinformatics pipeline.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector:
  • Biotechnology - R&D Services
Subsector:
  • Other
  • Analytical services
  • Bioinformatics
  • Diagnostic services
  • Genomics
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • R&D
  • Service company
Customer segments:
  • Other
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
Summary Products / Services / Technologies
Number of Medtech Products
On the market:4
Description of products:
Comprehensive Molecular Tumor Analysis (CMTA)
RNASeq
Whole genome sequencing (WGS)
Whole exome sequencing (WES)
Microbiome Sequencing (WGS)
Next Generation Sequencing Data analysis
Bioinformatics data analysis
Technology used:
Alacris CMTATM
MGI DNBSEQ and Illumina NGS Sequencing Technologies
ModCell™ technology (R&D)
© 2024 Biotechgate by Venture Valuation
X